Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenu-G
- Development stage
- Unknown
- Lead developer
- Epicon Lifesciences
- Administration
- Oral
01
Overview
Fenu-G is a nutraceutical herbal product developed and marketed by Epicon Lifesciences. It is derived from fenugreek (*Trigonella foenum-graecum*) and is primarily indicated for the management of blood glucose levels in patients with diabetes. Fenugreek extracts are known to contain bioactive compounds such as 4-hydroxyisoleucine, trigonelline, and galactomannan fibers, which contribute to its hypoglycemic effects by slowing carbohydrate absorption, stimulating insulin secretion, and improving insulin sensitivity. Fenu-G is positioned within Epicon's human health portfolio under the diabetes and general nutrition categories.
- Brand names
- Fenu-G
- Other names
- fenugreek extract
02
Targets
INSR (Insulin receptor)Sucrase-Isomaltase
Beyond the preview
Go deeper on Fenu-G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fenu-G.